Chlorpromazine dose for people with schizophrenia

Cochrane Database of Systematic Reviews

Volumn , Issue 2, 2009, Pages

  Liu, Xiaomeng ^a   De Haan, Saskia ^a  

^a UTRECHT UNIVERSITY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CHLORPROMAZINE;

AKATHISIA; BEHAVIOR; BIBLIOGRAPHIC DATABASE; BRIEF PSYCHIATRIC RATING SCALE; CARDIOVASCULAR DISEASE; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL GLOBAL IMPRESSION SCALE; CLINICAL TRIAL; COCHRANE LIBRARY; COGNITION; DATA ANALYSIS; DATA EXTRACTION; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG MEGADOSE; DRUG WITHDRAWAL; DYSTONIA; ENDOCRINE DISEASE; EXTRAPYRAMIDAL SYNDROME; EYE DISEASE; FUNCTIONAL STATUS; HEALTH CARE COST; HEALTH CARE QUALITY; HOSPITALIZATION COST; HUMAN; INFORMATION PROCESSING; LOW DRUG DOSE; MENTAL HEALTH; METABOLIC DISORDER; MORTALITY; MOTOR DYSFUNCTION; NEGATIVE SYNDROME; OUTCOME ASSESSMENT; POSITIVE SYNDROME; PSYCHOSIS; RATING SCALE; RELAPSE; REVIEW; RISK FACTOR; SCHIZOPHRENIA; SENSITIVITY ANALYSIS; SKIN MANIFESTATION; SOCIAL BEHAVIOR; SYSTEMATIC ERROR; SYSTEMATIC REVIEW; TREATMENT FAILURE; TREATMENT RESPONSE; UROGENITAL TRACT DISEASE;

EID: 65349116414     PISSN: 1469493X     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD007778     Document Type: Review

References (63)

1. Chouinard G, Annable L. Alpha-methyldopa-chlorpromazine combination in schizophrenic patients. Neuropsychobiology 1976;2(2-3): 118-126 [MEDLINE: 77100752; MEDLINE: 796755]
2. Clark M, Dubowski K, Colmore J. The effect of chlorpromazine on serum cholesterol in chronic schizophrenic patients. Clinical Pharmacology and Therapeutics 1970;11:883-889
3. Clark ML, Ramsey HR, Ragland RE, Rahhal DK, Serafetinides EA, Costiloe JP. Chlorpromazine in chronic schizophrenia: behavioral dose-response relationships. Psychopharmacologia 1970;18:260-70.
4. * Clark ML, Ramsey HR, Rahhal DK, Serafetinides EA, Wood FD, Costiloe JP. Chlorpromazine in chronic schizophrenia. The effect of age and hospitalization on behavioral dose-response relationships. Archives of General Psychiatry 1972;27(4):479-483 [MEDLINE: 5072717; MEDLINE: 73007937]
5. Serafetinides EA, Willis D, Clark ML. EEG dose-response relationships of chlorpromazine in chronic schizophrenia: the effects on the various rhythms and on alpha blocking. Biological Psychiatry 1972; 4:251-256
6. Gardos G, Cole JO, La Brie RA. A 12 year follow up study of chronic schizophrenics.. Hospital and Community Psychiatry 1982;33(12): 983-4.
7. * Prien RF, Cole JO. High dose chlorpromazine therapy in chronic schizophrenia. Report of National Institute of Mental Health - psychopharmacology research branch collaborative study group. Archives of General Psychiatry 1968;18(4):482-495 [MEDLINE: 4868797; MEDLINE: 68195283]
8. Prien RF, Cole JO, Belkin NF. Relapse in chronic schizophrenics following abrupt withdrawal of tranquillizing medication. British Journal of Psychiatry 1968;115(523):679-686 [MEDLINE: 5806858; MEDLINE: 69279244]
9. Prien RF, De Long SL, Cole JO, Levine J. Ocular changes occurring with prolonged high dose chlorpromazine therapy. Results from a collaborative study. Archives of General Psychiatry 1970;23(5):464-468 [MEDLINE: 5478574; MEDLINE: 71030994]
10. Prien RF, Levine J,Cole JO. Indications for high dose chlorpromazine therapy in chronic schizophrenia. Diseases of the Nervous System1970; 31(11):739-745 [MEDLINE: 4923151; MEDLINE: 71064134]
11. Wode-Helgodt B, Borg S, Fyro B, Sedvall G.Clinical effects and drug concentrations in plasma and cerebrospinal fluid in psychotic patients treated with fixed doses of chlorpromazine. Acta Psychiatrica Scandinavica 1978;58(2):149-173 [MEDLINE: 358755; MEDLINE: 79018181] (Pubitemid 8388613)
12. Andrews P, Hall JN, Snaith RP. A controlled trial of phenothiazine withdrawal in chronic schizophrenic patients. British Journal of Psychiatry 1976;128:451-455 [MEDLINE: 76207092; MEDLINE: 776312]
13. Bartko G, Sztaniszlav D,Olajos S, Bekesy M. Serum chlorpromazine and prolactin levels in paranoid schizophrenic patients and clinical response. Regional Symposium of the World. European Journal of Psychiatry 1988;2(2):109-117
14. Clark ML, Ray TS, Paredes A, Costiloe JP, Chappell JS, Hagans JA, Wolf S. Chlorpromazine in chronic schizophrenic women: I. Experimental design and effects at maximum point of treatment. Psychopharmacologia 1961;2:107-136
15. Clark ML, Kaul PN. A preliminary report on clinical response and blood levels of chlorpromazine and its sulfoxide during chlorpromazine therapy in chronic schizophrenic patients. In: Gottschalk LA, Merlis S editor(s). Pharmacokinetics of psychoactive drugs. New York, USA: Spectrum Publications, 1976:191-197 [MEDLINE: 1105638; MEDLINE: 76079180]
16. Clark ML, Kaul PN, Whitfield LR. Chlorpromazine kinetics and clinical response. Psychopharmacology Bulletin 1978;14(3):43-45 [MEDLINE: 353870; MEDLINE: 78226964]
17. Crane GE. Tardive dyskinesia in schizophrenic patients treated with psychotropic drugs. Agressologie 1968;9(2):209-216 [MEDLINE: 5675488; : PsycINFO]
18. Curry SH. Antipsychotic drugs. I. chlorpromazine: Pharmacokinetics, plasma levels and clinical response. In: Burrows GD, Norman T editor(s). Plasma levels of psychotropic drugs and clinical response. New York Basel: Marcel Dekker, 1978.
19. Curry SH.Metabolism and kinetics of chlorpromazine in relation to effect. In: Sedvall G, Uvnas B, Zotterman Y editor(s). Antipsychotic drugs: pharmacodynamics and pharmacokinetics. Oxford: Pergamon Press, 1976:343-352.
20. Green JF, King DJ. The effects of chlorpromazine and lorazepam on abnormal antisaccade and no-saccade distractibility. Biological Psychiatry 1998;44:709-715
21. Green JF, McElholm A, King DJ. A comparison of the sedative and amnestic effects of chlorpromazine and lorazepam. Psychopharmacology 1996;128:67-73. (Pubitemid 26379268)
22. Janakiramaiah N, Channabasavanna SM, Narashimha Murthy NS. ECT-chlorpromazine combination versus chlorpromazine alone in acutely schizophrenic patients. Acta Psychiatrica Scandinavica 1982; 66(6):464-470 [MEDLINE: 7180565; MEDLINE: 83096630] (Pubitemid 13242404)
23. Schiele B. Comparison of low and high dosage procedures in chlorpromazine therapy. Psychiatric quarterly 1959;33:252-259
24. Adams CE,Awad G, Rathbone J,Thornley B.Chlorpromazine versus placebo for schizophrenia. Cochrane Database of Systematic Reviews 2007, Issue 2. [DOI: 10.1002/14651858.CD000284]
25. Altman DG, Bland JM. Detecting skewness from summary information. BMJ 1996;313:1200. [: OLZ020600]
26. Armitage P. Statistical methods in medical research. Oxford-Edinburgh: Blackwell Scientific Publications, 1971.
27. RJBaldessarini, BMCohen,MHTeicher. Significance of neuroleptic dose and plasma level in the pharmacological treatment of psychoses. Archives of General Psychiatry 1988;45:7991.
28. Bland JM. Statistics notes. Trials randomised in clusters. BMJ 1997; 315:600.
29. Boissel J P, Cucherat M, Li W, Chatellier G, Gueyffier F, Buyse M, Boutitie F,Nony P,Haugh M,Mignot G. The problem of therapeutic efficacy indices. 3. Comparison of the indices and their use. Therapie 1999;54(4):405-411
30. P Bollini. Antipsychotic drugs: ismore worse? Ameta analysis of the published randomised control trials. Psychological Medicine 1994;24: 307-316
31. Carlsson A, Lindqvist M. Effect of chlorpromazine or haloperidol on formation of 3-methoxytyramine or normetanephrine in mouse brain. Acta Pharmacologica et Toxicologica 1963;20:140-144
32. Carpenter WT Jr, Buchanan RW. Schizophrenia. New England Journal of Medicine 1994;330(10):681-690
33. Correll CU. Acute and long-term adverse effects of antipsychotics. CNS spectrums 2007;12(12 Suppl 21):10-14
34. David JM. Dose equivalence of the antipsychotic drugs. Journal of Psychiatric Research 1974;11:65-69
35. Davis JM, Garver DL. Neuroleptics: clinical use in psychiatry. In: Iverson A, Iverson B, Snyder C editor(s). Handbook of psychopharmacology. Plenum, 1978.
36. JM Davis, JT Barter, JM Kane. Antipsychotic drugs. In: HJ Kaplan, BJ Saddock editor(s). Comprehensive textbook of psychiatry. 5th Edition. Batimore: Williams and Wilkins, 1989:1591-1626
37. Deeks J. Issues in the selection for meta-analyses of binary data. Proceedings of the 8th International Cochrane Colloquium; 2000 Oct 25-28th; Cape Town, South Africa. Capr Town, 2000.
38. Divine GW, Brown JT, Frazer LM. The unit of analysis error in studies about physicians' patient care behavior. Journal of General Internal Medicine 1992;7:623-629
39. Donner A, Klar N. Issues in the meta-analysis of cluster randomized trials. Statistics in Medicine 2002;21:2971-2980
40. Egger M, Davey-Smith G, Schneider M, Minder CSO. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;13:629-634 (Pubitemid 27387172)
41. Elbourne DR, Altman DG, Higgins JP, Curtin F,Worthington HV, Vail A. Meta-analyses involving cross-over trials: methodological issues. International Journal of Epidemiol 2002;31(1):140-149 (Pubitemid 34284916)
42. Endicott J, Spitzer R,Gleiss J,Cohen CJ. The global assessment scale. A procedure to measuring overall severity of psychiatric disturbance. Archives of General Psychiatry 1976;33:766-771
43. Geddes JR, Freemantle N, Harrison P, Bebbington PE. Atypical antipsychotics in the treatment of schizophrenia: a systematic overview and meta-regression analysis. BMJ 2000;321:1371-1376
44. Gulliford MC, Ukoumunne OC, Chinn S. Components of variance and intraclass correlations for the design of community-based surveys and intervention studies: data from the Health Survey for England 1994. American Journal of Epidemiology 1999;149:876-883 (Pubitemid 29196701)
45. Guy,W. Early clinical drug evaluation (ECDEU) assessment manual for psychopharmacology. Washington, DC: National Institute of Mental Health, 1976:217-222
46. Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327:557-560
47. Higgins, JPT,Green S (editors). Cochrane Handbook for systematic reviews of interventions 5.0.1 [updated September 2008]. The Cochrane Collaboration, 2008.
48. Hirsch SR, et al. Schizophrenia. 2nd Edition. Oxford: Blackwell Science Ltd, 2003.
49. Jüni P, Altman DG, Egger M. Systematic reviews in health care: Assessing the quality of controlled clinical trials. BMJ 2001;323: 42-46 (Pubitemid 32682008)
50. Leucht S, Wahlbeck K, Hamann J, Kissling W. New generation antipsychotics versus low-potency conventional antipsychotics: a systematic review and meta-analysis. Lancet 2003;361:1581-1589 (Pubitemid 36578993)
51. Lipka LJ, Lathers CM, Roberts J. Does chlorpromazine produce cardiac arrhythmia via the central nervous system?. Journal of Clinical Pharmacology 1988;28(11):968-983 (Pubitemid 19013407)
52. Lorr M, Klett CJ. Inpatientmultidimensional psychiatric scale manual. Palo Alto: Consulting Psychologists Press, 1966.
53. Marshall M, Lockwood A, Bradley C, Adams C, Joy C, Fenton M. Unpublished rating scales: a major source of bias in randomised controlled trials of treatments for schizophrenia. British Journal of Psychiatry 2000;176:249-252 (Pubitemid 30179844)
54. Statistics on Mental Health. Factsheet. Mental Health Foundation 2003.
55. Overall JE, Gorham DR. The brief psychiatric rating scale. Psychological reports 1962;10:799-812
56. Seeman, P, Lee, T, Chau-Wong, M, Wong, K. Antipsychotic drug doses and neuroleptic/dopamine receptors. Nature 1976;261:717.
57. Seeman P. Atypical antipsychotics: mechanism of action. Canadian journal of psychiatry 2002 Feb;47(1):27-38.
58. Simpson GM, Angus JWS. A rating scale for extrapyramidal side effects. Acta Psychiatrica Scandinavacia 1970;212:11-19
59. Ukoumunne OC,Gulliford MC, Chinn S, Sterne JAC, Burney PGJ. Methods for evaluating area-wide and organisation-based intervention in health and health care: a systematic review. Health Technology Assessment 1999;3(5):1-75.
60. Weinberger DR, et al. Prefrontal neurons and the genetics of schizophrenia. Biological Psychiatry 2001;50(11):825-844
61. WHO. The world health report 2001 mental health: new understanding, new hope 2001.
62. WHO model list of essential medicines. World Health Organisation. 15th March 2007.
63. Xia J, Adams CE, Bhagat N, Bhagat V, Bhoopathi P, El-Sayeh H, Pinfold V, Takriti Y. The Leeds Outcomes Stakeholders Survey (LOSS) Study. Proceedings of the15th Cochrane Colloquium; 2007 Oct 23-27; Sao Paulo. Cochrane Collaboration, 2007:85. * Indicates the major publication for the study